Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

(2013) L. Malcovati et al.   BLOOD

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

(2013) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers for determining the prognosis in chronic myelogenous leukemia

(2013) Kendra Sweet et al.   Journal of Hematology & Oncology

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

(2013) Carlos Graux et al.   LEUKEMIA RESEARCH

Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid Leukemia

(2013) Elias Jabbour et al.   SEMINARS IN HEMATOLOGY

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

(2013) M. Levis   Hematology-American Society of Hematology Education Program

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

(2012) A. Wiestner   BLOOD

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

(2012) Hajime Asahina et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Danusertib, an aurora kinase inhibitor

(2012) Hielke J Meulenbeld et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

(2012) Ursula A. Matulonis et al.   GYNECOLOGIC ONCOLOGY

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment

(2012) Wenqing Qi et al.   LEUKEMIA RESEARCH

Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms

(2012) Raoul Tibes et al.   Molecular Diagnosis & Therapy

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

(2010) Anne M. Traynor et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia

(2008) Shaoguang Li   LEUKEMIA & LYMPHOMA